Testing

Mayo Clinic’s launch of eight new next-generation sequencing (NGS) panels is intended to improve the lives of patients and families living with inherited cardiac conditions by aiding in the diagnosis and management of these complex disorders. These disorders include hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, Noonan syndrome, Marfan syndrome, long QT syndrome, and Brugada syndrome.

By Kelley Luedke • April 9, 2015

The new RAS/RAF Targeted Gene Panel by Next Generation Sequencing, Tumor, test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. In this post, Dr. Ande Rumilla discusses the clinical significance, proper ordering scenarios, and the science behind the test.

By brentwestra • January 13, 2015

The new Histoplasma Antigen, Urine test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. This test should be ordered in individuals suspected to be infected with Histoplasma capsulatum.

By brentwestra • August 22, 2014

Mayo Medical Laboratories would like to remind its clients that samples should not be submitted to any reference laboratory for any type of testing if a patient is being investigated for a viral hemorrhagic fever (e.g., Ebola virus) or Middle East Respiratory Syndrome coronavirus. Testing for these infectious diseases must be coordinated with local public health authorities.

By Andy Tofilon • August 11, 2014

A new dementia autoimmune evaluation is now available. View this post to learn what providers should know about autoimmune dementia, our testing approach, as well as interpretation, follow-up, and additional considerations once the test has been ordered.

By brentwestra • July 30, 2014

A new encephalopathy autoimmune evaluation is now available. View this post to learn what providers should know about autoimmune encephalopathy, our testing approach, as well as interpretation, follow-up, and additional considerations once the test has been ordered.

By brentwestra • July 21, 2014

A new epilepsy autoimmune evaluation is now available. View this post to learn what providers should know about autoimmune epilepsy, our testing approach, as well as interpretation, follow-up, and additional considerations once the test has been ordered.

By brentwestra • July 10, 2014

A new Trichomonas vaginalis assay is now available. This test should be ordered in individuals suspected to be infected with Trichomonas vaginalis. View this post to watch a short three-minute video overview from Bobbi Pritt, M.D. and to view new test utilization pearls.

By Andy Tofilon • June 18, 2014

With the recent discovery of somatic calreticulin (CALR) mutations in the majority of essential thrombocythemia (ET) and primary myelofibrosis (PMF) patients lacking JAK2 or MPL mutations, Mayo Medical Laboratories now offers testing for the detection of CALR mutations.

By Andy Tofilon • May 14, 2014

The new CALR Mutation Analysis, Myeloproliferative Neoplasm (MPN) assay is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. This test should be ordered on patients with clinical suspicion of essential thrombocythemia or primary myelofibrosis.

By Andy Tofilon • May 12, 2014

Mayo Clinic and Mayo Medical Laboratories announce the launch of CANCP, a new gene panel cancer test to help tailor therapies to the individual patient based on the unique genomic signature of the patient’s tumor.

By Kelley Luedke • April 28, 2014

This new gene panel cancer test helps tailor therapies to the individual patient based on the unique genomic signature of the patient’s tumor. This test scans specific regions in 50 genes known to affect tumor growth and response to therapies. The test is now available to Mayo Clinic patients and to providers worldwide through Mayo Medical Laboratories.

By Andy Tofilon • April 24, 2014

Autoantibody evaluation expedites diagnosis of reversible autoimmune neurological diseases and cancer.

By brentwestra • April 21, 2014